Thursday, February 20, 2020

Thursday, February 20, 2020

Sen. Blumenthal calls on FDA to issue regulatory framework for CBD

U.S. Sen. Richard Blumenthal (D-CT) recently held a press conference in which he pleaded with the U.S. Food and Drug Administration (FDA) to establish a regulatory framework for the safe use of CBD.

Blumenthal showed various products such as CBD-infused seltzer water, gummies and beverages that he said may provide benefits to consumers.

“Hemp growers, manufacturers, food producers and, most important, consumers, all deserve a regulatory framework that will set rules for classification, labeling, marketing, quality and other important features so that we stop the Wild West claims and make available products that are truly helpful and beneficial to consumers,” Blumenthal said. “The treatment of pain, anxiety, inflammation and other kinds of maladies may be aided by CBD, and consumers deserve the benefits of those treatments but they also deserve to know the truth about the oils, lotions, gummies and other products that are out there.”   

Blumenthal added that there is a need to prevent and halt unconfirmed and inaccurate health claims.

Together with Sens. Patrick Leahy (D-VT), Jon Tester (D-MT), Tammy Duckworth (D-IL), Chuck Schumer (D-NY) and Kirsten Gillibrand (D-NY), Blumenthal signed and sent a letter to the FDA requesting to speed up the regulatory process.

Organizations in this Story

U.S. Senator Richard Blumenthal

More News

FDA Reporter